Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Leukemia & Lymphoma

Font Size

Leukemia Treatment Breakthrough

CLL Survival Far Greater With Drug Rituxan
WebMD Health News
Reviewed by Laura J. Martin, MD

Sept. 30, 2010 -- Adding Rituxan to standard chemotherapy for chronic lymphocytic leukemia (CLL) raises three-year survival to 65% and is now the gold standard therapy for most patients.

Until the results of the study were first reported at a December 2008 medical conference, nobody expected Rituxan to have such a dramatic effect in CLL. But the study, in 817 CLL patients at 190 cancer centers in 11 nations, surprised experts, who were underwelmed by earlier reports.

A clinical trial "rarely has such a profound effect on the treatment of a disease," says Peter Hillmen, MD, PhD, of the U.K.'s Leeds Teaching Hospitals NHS Trust. Hillmen's editorial comments accompany the official report of the study results in the Oct. 2 issue of The Lancet.

CLL is the most common kind of leukemia in adults. It strikes five out of 100,000 people each year, mostly the middle-aged and elderly. The disease gets worse relatively slowly, and patients become less and less able to fight off infections.

By looking at biologic markers in CLL cancer cells, doctors can judge whether a patient is at high, intermediate, or low risk. Patients at highest risk -- about 8% of people with CLL -- have cancer cells that have lost a marker called p53.

The p53 marker is an Achilles heel that standard chemotherapy exploits. Rituxan does not work through p53, but because the new treatment must be used in combination with standard chemotherapy, it was not much help to patients with p53 loss.

But all others, including those with a marker of poor prognosis called 11q deletion, tend to respond quite well.

In the study, standard treatment with six courses of chemotherapy resulted in 45% survival after three years. Adding Rituxan to this therapy increased survival to 65%.

This treatment "changes the natural course of chronic lymphocytic leukemia," conclude study researchers Michael Hallek, MD, of the University of Cologne, Germany, and colleagues.

The study enrolled patients ranging in age from 30 to 81, but all were physically fit for their age. Because of the rigors of chemotherapy -- which increase with the addition of the new drug -- results may not be as good for patients who are in poor general health.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health